Effectiveness, cost, and safety of four regimens recommended by WHO for RR/MDR-TB treatment: a cohort study in Eastern China

References

• WHO. Global tuberculosis report 2022. Geneva: WHO; 2022.
   Google Scholar
• Resch SC, Salomon JA, Murray M, et al. Cost-effectiveness of treating multidrug-resistant tuberculosis. PLOS Med. 2006;3(7):1. doi: 10.1371/journal.pmed.0030241.
   Web of Science ®Google Scholar
• Lu P, Liu Q, Martinez L, et al. Time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis: a prospective cohort study from urban China. Eur Respir J. 2017;49(3):1601558. doi: 10.1183/13993003.01558-2016.
   PubMed Web of Science ®Google Scholar
• Falzon D, Schünemann HJ, Harausz E, et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J. 2017;49(3):1602308. doi: 10.1183/13993003.02308-2016.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO treatment guidelines for multidrug-and rifampicin-resistant tuberculosis. 2018 update. Geneva: World Health Organization; 2018.
   Google Scholar
• World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2019.
   Google Scholar
• Lan Z, Ahmad N, Baghaei P, et al. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med. 2020;8(4):383–11. doi: 10.1016/S2213-2600(20)30047-3.
   PubMed Web of Science ®Google Scholar
• Prasad R, Singh A, Gupta N. Adverse drug reactions in tuberculosis and management. Indian J Tuberc. 2019;66(4):520–532. doi: 10.1016/j.ijtb.2019.11.005.
   PubMedGoogle Scholar
• Van Deun A, Maug AKJ, Salim MAH, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010;182(5):684–692. doi: 10.1164/rccm.201001-0077OC.
   PubMed Web of Science ®Google Scholar
• Nunn AJ, Phillips PPJ, Meredith SK, et al. A trial of a shorter regimen for rifampin-resistant tuberculosis. N Engl J Med. 2019;380(13):1201–1213. doi: 10.1056/NEJMoa1811867.
   PubMed Web of Science ®Google Scholar
• Abidi S, Achar J, Assao Neino MM, et al. Standardised shorter regimens versus individualised longer regimens for multidrug-resistant TB. Eur Respir J. 2019;55(3):1901467. doi: 10.1183/13993003.01467-2019.
   Web of Science ®Google Scholar
• Pooran A, Pieterson E, Davids M, et al. What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa? PLOS One. 2013;8(1):e54587. doi: 10.1371/journal.pone.0054587.
   PubMed Web of Science ®Google Scholar
• Van Deun A, et al. Drug resistance monitoring: combined rates may be the best indicator of programme performance. Int J Tuberc Lung Dis. 2004;8(1):23–30.
   PubMed Web of Science ®Google Scholar
• Aung KJM, Van Deun A, Declercq E, et al. Successful ‘9-month Bangladesh regimen’ for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis. 2014;18(10):1180–1187. doi: 10.5588/ijtld.14.0100.
   PubMed Web of Science ®Google Scholar
• Piubello A, Harouna SH, Souleymane MB, et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis. 2014;18(10):1188–1194. doi: 10.5588/ijtld.13.0075.
   PubMed Web of Science ®Google Scholar
• Kuaban C, Noeske J, Rieder HL, et al. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis. 2015;19(5):517–524. doi: 10.5588/ijtld.14.0535.
   PubMed Web of Science ®Google Scholar
• Trébucq A, Schwoebel V, Kashongwe Z, et al. Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries. Int J Tuberc Lung Dis. 2018;22(1):17–25. doi: 10.5588/ijtld.17.0498.
   PubMed Web of Science ®Google Scholar
• Yan L, Kan X, Zhu L, et al. Short-course regimen for subsequent treatment of pulmonary tuberculosis: a prospective, randomized, controlled multicenter clinical trial in China. Clin Ther. 2018;40(3):440–449. doi: 10.1016/j.clinthera.2018.01.013.
   PubMed Web of Science ®Google Scholar
• Du Y, Qiu C, Chen X, et al. Treatment outcome of a shorter regimen containing clofazimine for multidrug-resistant tuberculosis: a randomized control trial in China. Clin Infect Dis. 2020;71(4):1047–1054. doi: 10.1093/cid/ciz915.
   PubMed Web of Science ®Google Scholar
• Liu Q, Lu P, Shen Y, et al. Collateral impact of the coronavirus disease 2019 (COVID-19) pandemic on tuberculosis control in Jiangsu province, China. Clin Infect Dis. 2021;73(3):542–544. doi: 10.1093/cid/ciaa1289.
   PubMed Web of Science ®Google Scholar
• Migliori GB, Lange C, Girardi E, et al. Multicenter Italian study on resistance to anti-tuberculosis drugs/tuberculosis network in Europe trials study group. Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis. Eur Respir J. 2008;31(4):904–905. doi: 10.1183/09031936.00159807.
   PubMed Web of Science ®Google Scholar
• Khan FA, HamidSalim MA, du Cros P, et al. Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses. Eur Respir J. 2017;50(1):1–13.
   Web of Science ®Google Scholar
• Tang S, Yao L, Hao X, et al. Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China. Clin Infect Dis. 2015;60(9):1361–1367. doi: 10.1093/cid/civ027.
   PubMed Web of Science ®Google Scholar
• Ammerman NC, Swanson RV, Tapley A, et al. Clofazimine has delayed antimicrobial activity against Mycobacterium tuberculosis both in vitro and in vivo. J Antimicrob Chemother. 2016;72(2):455–461. doi: 10.1093/jac/dkw417.
   PubMed Web of Science ®Google Scholar
• Ausi Y, Santoso P, Sunjaya DK, et al. Between curing and torturing: burden of adverse reaction in drug-resistant tuberculosis therapy. Patient Prefer Adherence. 2021;15:2597–2607. doi: 10.2147/PPA.S333111.
   PubMed Web of Science ®Google Scholar
• Batte C, Namusobya MS, Kirabo R, et al. Prevalence and factors associated with non-adherence to multi-drug resistant tuberculosis (MDR-TB) treatment at Mulago National Referral Hospital, Kampala, Uganda. Afr Health Sci. 2021;21(1):238–247. doi: 10.4314/ahs.v21i1.31.
   PubMed Web of Science ®Google Scholar
• Shin S, Pasechnikov AD, Gelmanovaet IY, et al. Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia. Int J Tuberc Lung Dis. 2007;11(12):1314–1320.
   PubMed Web of Science ®Google Scholar
• Sagwa E, Mantel-Teeuwisse AK, Ruswa N, et al. The burden of adverse events during treatment of drug-resistant tuberculosis in Namibia. South Med Rev. 2012;5(1):6–13.
   PubMedGoogle Scholar
• Diel R, Sotgiu G, Andres S, et al. Cost of multidrug resistant tuberculosis in Germany—an update. Int J Infect Dis. 2021;103:102–109. doi: 10.1016/j.ijid.2020.10.084.
   PubMed Web of Science ®Google Scholar
• Wirth D, Dass R, Hettle R. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany. BMC Health Serv Res. 2017;17(1):182. doi: 10.1186/s12913-017-2118-2.
   PubMedGoogle Scholar